The Asia Pacific Castrate-resistant Prostate Cancer Market would witness market growth of 9.6% CAGR during the forecast period (2020-2026). In the Asia Pacific, the market for castrate-resistant prostate cancer is estimated to propel at a significant rate over the forecast period. It is due to the presence of key oncology companies and rising R&D investments in countries like China and Japan. On the other hand, it led to the increasing development of prostate cancer drugs. Furthermore, the cost of clinical trials is less in developing countries than in developed countries.
Chemotherapy is considered as the first treatment for Castrate-resistant Prostate Cancer (CRPC). It is one of the choices for treatment for CRPC. The approved chemotherapy drugs include docetaxel (Taxotere) with prednisone. Growing advancements in chemotherapy resulted in the formulation of second-line treatment with extending survival in mCRPC patients whose disease advanced after or during docetaxel therapy.
The advancement in technology for diagnostic tests for detecting prostate cancer is also estimated to propel the growth of global market of castration-resistant prostate cancer treatment. Although, the lack of awareness and unavailability of appropriate healthcare facilities in some emerging countries will restrict the market demand for castration-resistant prostate cancer treatment.
Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: Castrate-Resistant Prostate Cancer Market in Asia Pacific is expected to register a CAGR of 9.6% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Radiotherapy
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Companies Profiled
- Sanofi S.A.
- Johnson and Johnson
- Pfizer, Inc.
- Bayer AG
- Abbott Laboratories
- GlaxoSmithKline PLC (GSK)
- Northwest Biotherapeutics, Inc.
- Active Biotech AB
- Astellas Pharma, Inc.
- Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Castrate-Resistant Prostate Cancer Market, by Therapy
1.4.2 Asia Pacific Castrate-Resistant Prostate Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market
Chapter 4. Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
4.1 Asia Pacific Hormonal Therapy Market by Country
4.2 Asia Pacific Immunotherapy Market by Country
4.3 Asia Pacific Chemotherapy Market by Country
4.4 Asia Pacific Radiotherapy Market by Country
Chapter 5. Asia Pacific Castrate-resistant Prostate Cancer Market by Country
5.1 China Castrate-resistant Prostate Cancer Market
5.1.1 China Castrate-resistant Prostate Cancer Market by Therapy
5.2 Japan Castrate-resistant Prostate Cancer Market
5.2.1 Japan Castrate-resistant Prostate Cancer Market by Therapy
5.3 India Castrate-resistant Prostate Cancer Market
5.3.1 India Castrate-resistant Prostate Cancer Market by Therapy
5.4 South Korea Castrate-resistant Prostate Cancer Market
5.4.1 South Korea Castrate-resistant Prostate Cancer Market by Therapy
5.5 Singapore Castrate-resistant Prostate Cancer Market
5.5.1 Singapore Castrate-resistant Prostate Cancer Market by Therapy
5.6 Malaysia Castrate-resistant Prostate Cancer Market
5.6.1 Malaysia Castrate-resistant Prostate Cancer Market by Therapy
5.7 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market
5.7.1 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
TABLE 1 Asia Pacific Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 2 Asia Pacific Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 3 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 4 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 5 Asia Pacific Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 6 Asia Pacific Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 7 Asia Pacific Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 8 Asia Pacific Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 9 Asia Pacific Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 10 Asia Pacific Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 11 Asia Pacific Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 12 Asia Pacific Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 13 Asia Pacific Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 14 Asia Pacific Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 15 China Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 16 China Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 17 China Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 18 China Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 19 Japan Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 20 Japan Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 21 Japan Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 22 Japan Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 23 India Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 24 India Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 25 India Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 26 India Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 27 South Korea Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 28 South Korea Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 29 South Korea Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 30 South Korea Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 31 Singapore Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 32 Singapore Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 33 Singapore Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 34 Singapore Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 35 Malaysia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 36 Malaysia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 37 Malaysia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 38 Malaysia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 39 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 40 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 41 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 42 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 43 Key Information – Sanofi S.A.
TABLE 44 Key information –Johnson and Johnson
TABLE 45 Key Information – Pfizer, Inc.
TABLE 46 Key Information – Bayer AG
TABLE 47 Key Information – Abbott Laboratories
TABLE 48 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 49 Key Information – Northwest Biotherapeutics, Inc.
TABLE 50 Key Information – Active Biotech AB
TABLE 51 key information – Astellas Pharma, Inc.
TABLE 52 Key Information – Dendreon Pharmaceuticals LLC
List of Figures
FIG 1 Methodology for the research